{"id":"pex168-100-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PEX168 is a pegylated exenatide derivative designed to provide extended duration of action compared to immediate-release GLP-1 agonists. It binds to and activates the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion, while simultaneously suppressing glucagon secretion and slowing gastric emptying to improve glycemic control in type 2 diabetes.","oneSentence":"PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:49.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02477969","phase":"PHASE3","title":"Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":587},{"nctId":"NCT02477865","phase":"PHASE3","title":"Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2014-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":406}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polyethylene Glycol Loxenatide"],"phase":"phase_3","status":"active","brandName":"PEX168(100µg)","genericName":"PEX168(100µg)","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEX168(100µg) is a protein-based intervention being studied in a Phase III clinical trial for the treatment of Type 2 Diabetes Mellitus. PEX168 is a synthetic protein that is administered in combination with metformin in this trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}